CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule

DOI PDF Web Site 参考文献39件 オープンアクセス

抄録

<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>We recently reported the relapse-free survival (RFS) significance of the combination of CD4<jats:sup>+</jats:sup> and forkhead box P3<jats:sup>+</jats:sup> (FOXP3) T-cell densities identified by immunohistochemistry in patients with stage I, II, and III colorectal cancer (CRC) who underwent curative resections. This study was designed to determine the optimal combination of markers that predict recurrence in patients with T factors of T3/T4a stage II CRC by applying a novel Bayes decision rule.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Using 137 cancer tissue specimens from T3/T4a stage II patients, 12 clinicopathologic and immune factors were analysed as predictive candidates for recurrence.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Our study showed that the combination of low CD4<jats:sup>+</jats:sup> and low FOXP3<jats:sup>+</jats:sup> T-cell densities resulted in extremely poor RFS.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Adjuvant chemotherapy may be considered for patients with a combination of low CD4<jats:sup>+</jats:sup> and low FOXP3<jats:sup>+</jats:sup> T-cell densities. The discovery of this new prognostic indicator is important for the appropriate management of patients undergoing curative resection for T3/T4a stage II CRC.</jats:p> </jats:sec>

収録刊行物

  • BMC Cancer

    BMC Cancer 22 (1), 2022-10-18

    Springer Science and Business Media LLC

参考文献 (39)*注記

もっと見る

関連プロジェクト

もっと見る

問題の指摘

ページトップへ